11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Dihydrotestosterone (DHT) is regarded as the most potent natural androgen and is implicated in the development and progression of castration resistant prostate cancer (CRPC). Under castrate conditions, DHT is produced from the metabolism of the adrenal androgen precursors, DHEA and androstenedione. Recent studies have shown that the adrenal steroid 11β-hydroxyandrostenedione (11OHA4) serves as the precursor to the androgens 11-ketotestosterone (11KT) and 11-ketodihydrotestosterone (11KDHT). In this study we comprehensively assess the androgenic activity of 11KT and 11KDHT. This is the first study, to our knowledge, to show that 11KT and 11KDHT, like T and DHT, are potent and efficacious agonists of the human androgen receptor (AR) and induced both the expression of representative AR-regulated genes as well as cellular proliferation in the androgen dependent prostate cancer cell lines, LNCaP and VCaP. Proteomic analysis revealed that 11KDHT regulated the expression of more AR-regulated proteins than DHT in VCaP cells, while in vitro conversion assays showed that 11KT and 11KDHT are metabolized at a significantly lower rate in both LNCaP and VCaP cells when compared to T and DHT, respectively. Our findings show that 11KT and 11KDHT are bona fide androgens capable of inducing androgen-dependant gene expression and cell growth, and that these steroids have the potential to remain active longer than T and DHT due to the decreased rate at which they are metabolised. Collectively, our data demonstrates that 11KT and 11KDHT likely play a vital, but overlooked, role in the development and progression of CRPC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig 2 Binding of DHT, T, 11KDHT and 11KT to the human AR (A) and transactivation via an ARE (B and C). Binding affinities, agonist potencies and efficacies of DHT, 11KDHT, T and 11KT relative to the synthetic AR agonist mibolerone are summarised in (D). Whole cell binding assays (A) were conducted in COS-1 cells transiently transfected with pSVARo. Cells were incubated with 0.2 nM [3H]-Mib in the absence and presence of increasing concentrations of either unlabelled Mib, DHT, 11KDHT, T and 11KT for 16 hours. Results are plotted as % specific binding where the total specific binding of [3H]-Mib only is set to 100% and binding of unlabelled steroid is set as a % binding relative to that. Whole cell binding results are shown as means ± SEM of three independent experiments performed in triplicate. Transactivation assays (B and C) where performed in COS-1 cells transiently transfected with the pSVARo expression vector and the 4xSC ARE1.2-luc reporter. Agonist activity was measured by incubating cells in the presence of increasing concentrations of either Mib, DHT, T, 11KDHT or 11KT for 24 h. Induction is shown as % luciferase activity expressed in relative light units (rlu’s), with the maximal response of Mib (10−5 M) set to 100%. Luciferase assays are shown as means ± SEM of six independent experiments performed in quadruplicate.](https://figures.cochat.ai/paper-figures/99618cf761a440d99d5228b87dbb6f76/11-ketotestosterone-and-11-ketodihydrotestosterone-in-castration-resistant-figure-2.jpg)
![Fig 3 Induction of AR-regulated gene expression in LNCaP cells by DHT, 11KDHT and 11KT. Cells were incubated with CS-FCS-supplemented media for 24 hours prior to treatment with 1 or 10 nM steroid for an additional 24 hours prior to analysis by qPCR. Gene expression was calculated relative to the geometric mean of the reference genes ALAS and PBGD. Fold change over vehicle was calculated using the method described by Pfaffl et al [48]. Results are shown as means ± SEM of three independent experiments performed in triplicate. Data from individual experiments was all normalized using log transformation and mean-centering prior to analysis [49].](https://figures.cochat.ai/paper-figures/041a5f66ce2c452490998750f1db4851/11-ketotestosterone-and-11-ketodihydrotestosterone-in-castration-resistant-figure-3.jpg)
![Fig 4 Induction of AR-regulated gene expression in VCaP cells by DHT, 11KDHT, T and 11KT. Cells were incubated with CS-FCS supplemented media for 24 hours prior to treatment with 1 or 10 nM steroid for an additional 24 hours prior to analysis by qPCR. Gene expression was calculated relative to the geometric mean of the reference genes ALAS and PBGD and are expressed as the fold change over the vehicle control. Results are shown as means ± SEM of three independent experiments performed in triplicate. Data from individual experiments was all normalized using log transformation and mean-centering prior to analysis [49].](https://figures.cochat.ai/paper-figures/10542b2cdd9f4e1fbc1285f06a05c43b/11-ketotestosterone-and-11-ketodihydrotestosterone-in-castration-resistant-figure-4.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“11KA4 in turn serves as a substrate for AKR1C3 expressed in peripheral tissues such as adipose tissue, yielding 11KT, which binds and activates the human androgen receptor with an affinity and potency similar to that of testosterone [45,[70], [71], [72]].”
From Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: a comprehensive review (2019) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“11KT is a potent androgen, with bioactivity similar to that of T (25–27).”
From 24-Hour Profiles of 11-Oxygenated C19 Steroids and Δ5-Steroid Sulfates during Oral and Continuous Subcutaneous Glucocorticoids in 21-Hydroxylase Deficiency (2021) · cites this paper as [27]
The cited source says what the claim attributes to it.
In the citing paper
“11KT can activate androgen-dependent processes with a similar potency to T12”
From Steroid hormone profiling reveals altered adrenal androgen production in endometriosis (2026) · cites this paper as [12]
In the citing paper
“including, 11ketotestosterone and 11-keto-DHT, androgens that bind and activate the androgen receptor.128,129”
From Congenital adrenal hyperplasia (2017) · cites this paper as [128]
In the citing paper
“While 11OHT and 11OHDHT represent partial AR agonists, 11KT and 11KDHT are full agonists with the same AR activating potential as T and DHT, respectively (Pretorius et al., 2016, Storbeck et al., 2013).”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as Pretorius et al., 2016
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610
Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction
Ye, J., Coulouris, G., Zaretskaya, I., Cutcutache, I., Rozen, S., & Madden, T. L. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-134 · Cited by 6,111 · cited 1×
“Reference genes: PBGD [28]: 5’-CATGTCTGGTAACGGCAATG-3’ (forward) and 5’GTACG AGGCTTTCAATGTTG-3’ (reverse), ALAS [29]: 5’-TTCCACAGGAGCCAGCATAC-3’ (forward) and 5’-GGACCTTGGCCTTAGCAGTT-3’ (reverse).”
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · cited 1×
“Recent clinical trials demonstrating beneficial clinical outcomes after treatment with the AR antagonist enzalutamide [7] and the CYP17A1 inhibitor abiraterone [8–10] have highlighted the continued androgen dependency of CRPC.”
BackgroundAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
LNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., & Mulder, E. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80067-1 · Cited by 950 · cited 1×
“LNCaP cells express a mutated AR (T877A) [32], while VCaP cells express the wild type AR.”
BackgroundAttard, G., Reid, A. H. M., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., Messiou, C., Molife, L. R., Maier, G., Thompson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0642 · Cited by 605
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577 · cited 1×
“The AR and AR-regulated genes are expressed in most clinical cases of CRPC demonstrating that the AR axis is reactivated and drives tumour growth [4,5].”
BackgroundStandardization of real-time PCR gene expression data from independent biological replicates
Willems, E., Leyns, L., & Vandesompele, J. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.04.036 · Cited by 490 · cited 1×
“Data from individual experiments was all normalized using log transformation and mean-centering prior to analysis [49].”
Method
Cited by
Congenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Witchel, S. F., Oberfield, S. E., & Peña, A. S. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00078 · Cited by 653
“Testosterone, DHT, 11-ketotestosterone, and 11-ketodihydrotestosterone bind to the human ARand promote AR-regulated gene expression [33].”
BackgroundSchiffer, L., Barnard, L., Baranowski, E. S., Gilligan, L. C., Taylor, A. E., Arlt, W., Shackleton, C. H. L., & Storbeck, K.-H. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105439 · Cited by 450
Self-citation11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome
O’Reilly, M. W., Kempegowda, P., Jenkinson, C., Taylor, A. E., Quanson, J. L., Storbeck, K.-H., & Arlt, W. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3285 · Cited by 267
Self-citationSteroidogenesis: Unanswered Questions
Miller, W. L. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.09.002 · Cited by 226
Metadata
- Authors
- Pretorius, E., Africander, D. J., Vlok, M., Perkins, M. S., Quanson, J., & Storbeck, K.-H.
- Affiliations
- Stellenbosch University (ZA)
- Corresponding author
- Pretorius, Elzette
- Africander, Donita J.
- Vlok, Maré
- Perkins, Meghan S.
- Quanson, Jonathan
- Storbeck, Karl-Heinz
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-07-21
- Volume
- 11
- Issue
- 7
- Pages
- e0159867
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4956299
- OpenAlex
- W2501835417
- Cited by
- 148
- References
- 55
- Citations by year
- 2026: 14 · 2025: 10 · 2024: 11 · 2023: 13 · 2022: 18 · 2021: 20 · 2020: 20 · 2019: 15 · 2018: 12 · 2017: 11 · 2016: 4
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- SUNScholar (Stellenbosch University) (submittedVersion)
- Funders
- National Research Foundation of South Africa (TTK1206061092)
- Cancer Association of South Africa
- Universiteit Stellenbosch
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- 11-ketotestosterone, castration-resistant prostate cancer, androgen receptor, 11β-hydroxyandrostenedione, androgen metabolism, androgen-dependent gene expression, prostate cancer cell proliferation, LNCaP cells, VCaP cells
- MeSH terms
- Androgens, Animals, Humans, Male, Protein Binding, Receptors, Androgen, Testosterone, Response Elements, Cell Line, Tumor, Cell Proliferation, Biosynthetic Pathways, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored. https://app.cochat.ai/papers/10.1371/journal.pone.0159867
- The paper
- Pretorius, E., Africander, D. J., Vlok, M., Perkins, M. S., Quanson, J., & Storbeck, K.-H. (2016). 11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored. PLOS ONE. https://doi.org/10.1371/journal.pone.0159867
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.